|
Feb 12
|
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
|
|
Feb 11
|
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
|
|
Feb 10
|
Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer
|
|
Feb 10
|
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
|
|
Oct 10
|
FDA Grants iota Biosciences IDE Approval for First-In-Human Early Feasibility Study with Implantable Bladder Device
|
|
Oct 10
|
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause
|
|
Oct 9
|
Protein prediction wins chemistry Nobel; Alnylam submits an all-important drug application
|
|
Oct 8
|
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
|
|
Aug 28
|
EC approves Astellas’ PADCEV for urothelial cancer
|
|
Aug 27
|
European Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer
|
|
Aug 27
|
Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy
|
|
Jul 26
|
Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer
|
|
Jul 26
|
Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
|
|
Jun 26
|
Pharma M&A: The top high value deals in 2023
|
|
Jun 20
|
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $10 (or More), Say Analysts
|
|
May 21
|
Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies
|
|
May 8
|
Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
|
|
May 2
|
Xyphos and Poseida to develop allogeneic cell therapies for cancer
|
|
May 2
|
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
|
|
Mar 22
|
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
|